Form 4: IO Biotech General Counsel Acquires 12,000 Shares

IO Biotech's General Counsel, Devin Whittemore Smith, acquired 12,000 shares of common stock at $0.81 per share on December 23, 2024.

Summary

• Devin Whittemore Smith, the General Counsel of IO Biotech, Inc., purchased 12,000 shares of the company's common stock.
• The transaction occurred on December 23, 2024.
• The purchase price was $0.81 per share.
• Following the transaction, Mr. Smith directly owns 16,938 shares of IO Biotech common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine insider purchase, which is generally neutral to slightly positive. It indicates confidence from the General Counsel but is not a major market-moving event.

Positives

• The purchase of shares by a company insider can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into management's view of the company's prospects. This transaction is a routine disclosure of an insider purchase.

Comparison to Industry Standards

• Insider trading activity is common across all publicly listed companies.
• The size of this transaction is relatively small compared to the overall market capitalization of IO Biotech.
• It is not unusual for company officers to acquire shares, especially at the current price.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment, as it indicates confidence from a company insider.

Key Dates

Keywords

IO Biotech, insider trading, stock acquisition, common stock, General Counsel, IOBT